Human Growth Hormone Global Market Report 2024

The human growth hormone market size has grown strongly in recent years. It will grow from $4.33 billion in 2023 to $4.75 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to improving healthcare infrastructure, increasing prevalence of growth disorders, expanding applications in sports medicine, rising awareness about hormone therapies, and growing geriatric population,.

The human growth hormone market size is expected to see strong growth in the next few years. It will grow to $6.93 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The anticipated growth during the forecast period can be credited to the emergence of personalized medicine, the increasing global healthcare expenditure, the growing adoption of recombinant DNA technology, the rising demand for hormone replacement therapies, and the increasing prevalence of endocrine disorders. Key trends expected during the forecast period include the expansion of distribution networks in emerging markets, the integration of artificial intelligence in drug development, a focus on sustainable manufacturing processes, the development of long-acting formulations, and the utilization of combination therapies to enhance efficacy.

The increasing awareness of treatment procedures is anticipated to drive the expansion of the human growth hormone market in the future. Treatment procedures encompass medical interventions aimed at alleviating, managing, or curing health conditions or diseases. This heightened awareness is fueled by advancements in medical technology, enhanced access to information via digital media, and a growing public interest in health and wellness. Human growth hormone (HGH) treatments have attracted significant media attention and public interest, underscoring the benefits and potential applications of modern medical interventions, thereby boosting overall awareness of treatment procedures. For example, according to the 2022 National Survey on Drug Use and Health (NSDUH) report by the Substance Abuse and Mental Health Services Administration (SAMHSA), among adolescents aged 12 to 17, in 2021, 40.6% of the 5 million adolescents with a past year Major Depressive Episode (MDE) received treatment for depression, while in 2022, 56.8% of the 4.8 million adolescents with a past year MDE received mental health treatment. Consequently, the heightened awareness of treatment procedures is propelling the growth of the human growth hormone market.

Leading companies in the human growth hormone market are intensifying their efforts in drug development and approvals to enhance their medication offerings and provide superior treatment solutions. Drug development entails a comprehensive and meticulous process involving multiple stages to ensure the safety, efficacy, and quality of a new drug before it is introduced to the market. For example, in June 2023, Pfizer Inc., a US-based biopharmaceutical company, and OPKO Health Inc., a US-based biopharmaceutical and diagnostics company, announced the approval of NGENLA (somatrogon-ghla) by the Food and Drug Administration (FDA). This treatment offers a more convenient dosing regimen and enhances patient adherence compared to daily injections. It provides children with growth hormone deficiency the option to reduce injection frequency from daily to once a week. The FDA approval was supported by a Phase 3 study demonstrating NGENLA's non-inferiority to once-daily somatropin, with a safety profile comparable to somatropin.

In April 2021, Merck KGaA, a German science and technology company, collaborated with PRA Health Science to improve the administration of growth hormone therapy. Through this partnership, Merck is able to present an all-encompassing digital health solution for addressing growth disorders and managing growth hormone therapy, offering a more individualized and efficient method for patient care. PRA Health Science, based in the US, provides a remote patient monitoring platform to assist in human growth hormone (HGH) treatments.

Major companies operating in the human growth hormone market are Pfizer Inc., Roche Holding AG, Novartis AG, Thermo Fisher Scientific Inc., Eli Lilly and Company, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Ipsen Pharma, Ferring Holding SA, Endo International, Zydus Lifesciences Limited, Opko Health, LG Life Sciences, EMD Serono Inc., Wockhardt Ltd., JCR Pharmaceuticals Co. Ltd., Genentech Inc., Shanghai United Imaging Healthcare Co. Ltd., SOFAR S.p.A., United Laboratories, Ascendis Pharma, Uni-Pharma S.A., Versartis Inc., Reliance Life Sciences, Anhui Anke Biotechnology (Group) Co. Ltd., Rani Therapeutics.

North America was the largest region in the human growth hormone market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human growth hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human growth hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Human growth hormone (HGH) is a peptide hormone originating from the pituitary gland, playing a vital role in encouraging growth, cell replication, and tissue renewal across the human body. It finds application in medical interventions targeting growth hormone deficiency, promoting muscle growth, and addressing age-related issues such as muscle atrophy and decreased bone density.

The primary forms of human growth hormone are liquid and powder. Liquid human growth hormone products are typically presented as a solution or suspension, readily available for immediate consumption or injection. These include various brands such as Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, Skytrofa, among others, administered via different routes such as oral, intravenous, intramuscular, or subcutaneous. These products are distributed through diverse channels such as hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, catering to a range of applications such as growth hormone (GH) deficiency, adult GH deficiency, pediatric GH deficiency, Turner syndrome, idiopathic short stature, Prader-Willi syndrome, small for gestational age, and others.

The human growth hormone market research report is one of a series of new reports that provides human Growth hormone market statistics, including human growth hormone industry global market size, regional shares, competitors with a human growth hormone market share, detailed human growth hormone market segments, market trends, and opportunities, and any further data you may need to thrive in the human growth hormone industry. This human growth hormone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human growth hormone market consists of sales of combination therapies, sustained-release formulations, long-acting formulations, biosimilar versions, pediatric-specific formulations, and personalized dosing regimens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.